Evogene Reports Q1 2026 Results as AgPlenus Herbicide and Fungicide Programs Advance

Key Takeaways

• Q1 2026 net loss $5.9 M, revenue $0.3 M vs $2.3 M prior year.
• AgPlenus herbicide work continues with Corteva; internal fungicide reaches lead optimization.
• Bayer‑AgPlenus herbicide partnership ended; assets revert to AgPlenus.
• ChemPass AI gains second Google Cloud partnership to add AI agents.
• Cash balance $13.1 M; quarterly burn $2.8 M supports pipeline development.

Pulse Analysis

Evogene’s first‑quarter results highlight a classic growth‑stage trade‑off: a widening loss as the company trims legacy operations while investing in next‑generation discovery tools. Revenue contraction reflects the wind‑down of the Casterra seed business, yet the firm’s cash position of $13.1 million provides a runway to fund its AI‑centric strategy. By emphasizing ChemPass, Evogene aims to accelerate small‑molecule design, positioning itself to capture market share in both agrochemicals and pharma once its pipelines mature.

The AgPlenus unit remains the engine of agricultural innovation. A partnership with Corteva continues to push herbicide candidates forward, and an internal fungicide program has entered lead optimization—a critical milestone that signals readiness for pre‑clinical testing. Conversely, the termination of the Bayer collaboration over the APTH1 target removes a short‑term revenue prospect but returns valuable IP to Evogene, allowing the company to repurpose the assets in future projects without licensing constraints.

Technology is the differentiator in Evogene’s playbook. The second Google Cloud collaboration announced in February embeds advanced AI agents into ChemPass, automating data generation and model refinement across complex scientific workflows. This integration not only reduces discovery timelines but also enhances predictive accuracy, a competitive edge in an industry where speed to market drives profitability. As AI adoption accelerates across agriscience, Evogene’s platform could become a cornerstone for partners seeking rapid, cost‑effective molecule design, potentially translating into new licensing deals and revenue streams in the coming years.